Overview

Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment

Status:
Completed

Trial end date:
2021-04-12

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety and tolerability of multiple oral doses of selgantolimod and to evaluate the antiviral activity of selgantolimod in adult participants with chronic hepatitis B (CHB) who are viremic and not currently being treated.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antiviral Agents